ADQ to boost healthcare, pharma portfolio with Amoun acquisition

ADQ to boost healthcare, pharma portfolio with Amoun acquisition

ABU DHABI / WAM

ADQ, one of the region's largest holding companies with a broad portfolio of major enterprises spanning key sectors of Abu Dhabi's diversified economy, announced on Wednesday that it has entered into a definitive agreement to acquire Amoun Pharmaceutical Company SAE (Amoun), one of Egypt's leading manufacturers, distributors and exporters of branded pharmaceutical and animal health products, from Bausch Health Companies Inc (Bausch Health). Amoun has a long-standing reputation for robust pharmaceuticals and life-sciences products, addressing a wide range of acute and chronic conditions and highly prevalent diseases that demand treatment with proven high-quality medications. The company's flagship products include Hibiotic, Antinal, Alphintern, and Neuroton. Amoun has more than 2,500 employees and owns one of the largest, state-of-the-art pharmaceutical plants in Egypt. Fahad Al Qassim, Executive Director, Healthcare & Pharma, at ADQ, said, "ADQ aims to develop an integrated healthcare and pharma value chain through strategic investments and new ventures both locally and internationally.“ The investment in Amoun further strengthens ADQ's long-term healthcare and pharma strategy to deliver a fully integrated value chain in the UAE.

"Together with our recent pharma manufacturing investments in the UAE and India, our investment in Amoun will further enhance our pharma strategy with